Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Other Operating Expenses (2016 - 2025)

Cumberland Pharmaceuticals (CPIX) has disclosed Other Operating Expenses for 16 consecutive years, with $9.5 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses rose 23.57% to $9.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $29.8 million through Dec 2025, up 5.09% year-over-year, with the annual reading at $29.8 million for FY2025, N/A changed from the prior year.
  • Other Operating Expenses hit $9.5 million in Q4 2025 for Cumberland Pharmaceuticals, up from $6.4 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $10.8 million in Q4 2023 to a low of $6.1 million in Q3 2021.
  • Historically, Other Operating Expenses has averaged $7.5 million across 5 years, with a median of $7.3 million in 2023.
  • Biggest five-year swings in Other Operating Expenses: skyrocketed 66.9% in 2023 and later fell 29.27% in 2024.
  • Year by year, Other Operating Expenses stood at $7.6 million in 2021, then decreased by 15.17% to $6.5 million in 2022, then skyrocketed by 66.9% to $10.8 million in 2023, then dropped by 29.27% to $7.7 million in 2024, then grew by 23.57% to $9.5 million in 2025.
  • Business Quant data shows Other Operating Expenses for CPIX at $9.5 million in Q4 2025, $6.4 million in Q3 2025, and $7.2 million in Q2 2025.